
Opinion|Videos|August 16, 2024
The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore the role of androgen receptor-targeted therapy in mCRPC.
Advertisement
Episodes in this series

- How do androgen receptor-targeted therapies, including abiraterone and enzalutamide, fit into the treatment paradigm, and when might you choose an androgen receptor-targeted therapy over other treatment options, or vice versa?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
4
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
5

















